Illumina Inc

US

ILMN

Health Care

120.25 ₽

Current price

Strong sell
120.25 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    206 / 240

  • Position in country

    12878 / 14179

  • Return on Assets, %

    -10.6

    -2.7

  • Net income margin, %

    -15.6

    -6.7

  • EBITDA margin, %

    1.6

    5.6

  • Debt to Equity, %

    25.9

    15.1

  • Intangible assets and goodwill, %

    54.7

    4.7

  • Revenue CAGR 3Y, %

    11.6

    12.8

  • Total Equity change 1Y, %

    -13

    -2.4

  • Revenue Y, % chg

    -1.8

    0

  • P/BV

    3.5

    2

  • P/S

    4.4

    4.1

  • EV/S

    4.5

    3.6

  • EV/EBITDA

    57.5

    7.8

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    18

    48.9

  • Forward P/E

    96.1

    25.5

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • IQVIA Holdings Inc

    00%

  • West Pharmaceutical Services Inc

    00%

  • Agilent Technologies Inc

    00%

  • Avantor Inc

    00%

  • Thermo Fisher Scientific Inc

    00%

  • Danaher Corp

    00%

  • Waters Corp

    00%

  • Mettler-Toledo International Inc

    00%

  • Revvity Inc

    00%

  • Illumina Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Life Sciences Tools & Services

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    20236.5

  • Ticker

    ILMN.O

  • ISIN

    US4523271090

  • IPO date

    2000-06-28

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-16

  • Date fact. publication of reports

    2023-12-31

Company Description

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: